54 studies found for:    Open Studies | "Neurofibromatoses"
Show Display Options
Rank Status Study
21 Not yet recruiting Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)
Condition: Neurofibromatosis Type 1 (NF1)
Intervention: Drug: Cholecalciferol
22 Recruiting Resiliency Training for Adolescent Neurofibromatosis Patients Via Videoconferencing With Skype
Condition: Neurofibromatoses
Interventions: Behavioral: Stress Management Group 1;   Behavioral: Stress Management Group 2
23 Recruiting Genetic Evaluation of NF1 and Scoliosis Patients
Conditions: Neurofibromatosis 1;   Scoliosis
Intervention: Other: Cheek swab
24 Recruiting Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Conditions: Neurofibromatosis Type 2;   Neuroma, Acoustic
Intervention: Drug: RAD001, everolimus
25 Recruiting Effect of Lamotrigine on Cognition in NF1
Condition: Neurofibromatosis Type 1
Interventions: Drug: Lamotrigine;   Drug: Placebo
26 Recruiting Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
Conditions: Neurofibromatosis Type 2;   Progressive Vestibular Schwannomas
Intervention: Drug: Bevacizumab
27 Recruiting The Cognitive Variability in NF1 and TSC Monozygotic Twins
Conditions: Neurofibromatosis Type I;   Tuberous Sclerosis Complex
Intervention:
28 Recruiting Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
Condition: Plexiform Neurofibromas
Intervention: Drug: Imatinib Mesylate
29 Recruiting PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
Conditions: Neurofibroma, Plexiform;   Precursor Cell Lymphoblastic Leukemia-Lymphoma;   Leukemia, Prolymphocytic, Acute;   Sarcoma
Intervention: Drug: PLX3397
30 Unknown  First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas
Condition: Cutaneous Neurofibromas
Intervention: Procedure: Erbium-YAG laser vaporization
31 Available Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
Conditions: Neurofibromatosis Type 2;   Severe Profound Sensorineural Hearing Loss
Intervention: Device: Nucleus Profile ABI541 Auditory Brainstem Implant
32 Recruiting Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With NF
Condition: Neurofibromatosis
Intervention: Other: Questionnaires
33 Recruiting Feasibility and Clinically Application of Magnetic Resonance Fingerprinting
Conditions: Neurofibromatosis Type 1;   Brain Tumor;   Glioma
Interventions: Device: Magnetic Resonance Imaging;   Device: Magnetic Resonance Fingerprinting
34 Unknown  Concentration and Activity of Lapatinib in Vestibular Schwannomas
Conditions: Vestibular Schwannoma;   NF2;   Neurofibromatosis 2;   Acoustic Neuroma;   Auditory Tumor
Intervention: Drug: lapatinib
35 Not yet recruiting Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Conditions: Metastatic Malignant Peripheral Nerve Sheath Tumor;   Neurofibromatosis Type 1;   Recurrent Malignant Peripheral Nerve Sheath Tumor
Interventions: Procedure: Computed Tomography;   Other: Laboratory Biomarker Analysis;   Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter;   Other: Quality-of-Life Assessment;   Procedure: Single Photon Emission Computed Tomography
36 Not yet recruiting Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients
Condition: Neurofibromatosis Type 1
Intervention:
37 Recruiting Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Conditions: Vestibular Schwannoma;   Meningioma;   Acoustic Neuroma;   Neurofibromatosis Type 2
Intervention: Drug: AR-42
38 Recruiting Effect of Implant Position on Magnetic Resonance Image Distortion
Condition: Neurofibromatosis Type 2
Intervention: Device: MR imaging
39 Recruiting Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
Conditions: Neurofibromatosis Type 2;   Vestibular Schwannomas;   Meningiomas
Intervention: Drug: RAD001
40 Recruiting Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Conditions: Neurofibromatosis Type 1;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Visual Pathway Glioma
Interventions: Drug: Lenalidomide;   Other: Pharmacological Study

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-54) Show next page of results    Last Page
Indicates status has not been verified in more than two years